Contineum Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Contineum Therapeutics Class
CTNM Stock   15.21  0.83  5.77%   
Contineum Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Contineum Therapeutics' valuation are provided below:
Market Capitalization
525.3 M
Enterprise Value Revenue
8.2516
Earnings Share
(2.25)
There are over one hundred seventeen available fundamental signals for Contineum Therapeutics Class, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to validate Contineum Therapeutics' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road.
Check Contineum Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Contineum Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 10.8 M, Interest Income of 10.8 M or Depreciation And Amortization of 221.4 K, as well as many indicators such as Price To Sales Ratio of 6.23, Dividend Yield of 0.0 or PTB Ratio of 3.26. Contineum financial statements analysis is a perfect complement when working with Contineum Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Contineum Stock
Check out the analysis of Contineum Therapeutics Correlation against competitors.

Contineum Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets127.7 M244.8 M94.9 M
Slightly volatile
Short and Long Term Debt Total6.8 M7.2 M16.4 M
Slightly volatile
Other Current Liabilities4.1 M7.7 M2.7 M
Slightly volatile
Total Current Liabilities7.3 M11.5 M5.1 M
Slightly volatile
Property Plant And Equipment Net7.8 M7.4 M1.9 M
Slightly volatile
Accounts Payable2.2 M2.1 M886.2 K
Slightly volatile
Cash13.1 M25.2 M8.1 M
Slightly volatile
Non Current Assets Total7.8 M7.4 M2.1 M
Slightly volatile
Non Currrent Assets Other3.3 K3.5 K152.1 K
Pretty Stable
Long Term Debt2.9 M3.3 M3.6 M
Slightly volatile
Cash And Short Term Investments122.7 M235.5 M92 M
Slightly volatile
Common Stock Shares Outstanding19 M17.4 M24 M
Slightly volatile
Short Term Investments109.6 M210.2 M83.9 M
Slightly volatile
Liabilities And Stockholders Equity127.7 M244.8 M94.9 M
Slightly volatile
Non Current Liabilities Total5.3 M5.5 M16.2 M
Pretty Stable
Other Current Assets1.7 M1.9 M1.1 M
Slightly volatile
Other Stockholder Equity380.8 M362.7 M64.9 M
Slightly volatile
Total Liabilities16.1 M17 M21.5 M
Slightly volatile
Property Plant And Equipment Gross9.9 M9.4 M3.1 M
Slightly volatile
Short and Long Term Debt2.9 M4.5 M2 M
Slightly volatile
Total Current Assets124.4 M237.3 M93 M
Slightly volatile
Capital Stock31.4 K29.9 K13.8 K
Slightly volatile
Non Current Liabilities Other94 K99 K1.3 M
Slightly volatile
Net Working Capital117 M225.9 M88 M
Slightly volatile
Short Term Debt1.6 M1.3 M1.5 M
Pretty Stable
Common Stock31.4 K29.9 K14.4 K
Slightly volatile
Other Assets0.80.90.9824
Slightly volatile

Contineum Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income10.8 M10.2 M2.1 M
Slightly volatile
Depreciation And Amortization221.4 K232.2 K302.1 K
Slightly volatile
Selling General Administrative8.5 M14.3 M7.2 M
Slightly volatile
Other Operating Expenses46.3 M58.5 M34.6 M
Slightly volatile
Research Development28.9 M43.9 M24.9 M
Slightly volatile
Total Operating Expenses46.1 M58.2 M34.5 M
Slightly volatile
Reconciled Depreciation221.4 K232.2 K302.1 K
Slightly volatile
Income Tax Expense380.1 K517.5 K302.3 K
Slightly volatile
Selling And Marketing Expenses166.7 K175.5 K658.7 K
Slightly volatile
Cost Of Revenue208.5 K232.2 K304.2 K
Slightly volatile

Contineum Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation8.2 M7.8 M2.8 M
Slightly volatile
Begin Period Cash Flow8.3 M14 M14.1 M
Slightly volatile
Other Cashflows From Financing Activities675.5 K711 K60 M
Slightly volatile
Depreciation221.4 K232.2 K302.1 K
Slightly volatile
Capital Expenditures333.9 K591.1 K234.5 K
Slightly volatile
End Period Cash Flow13.1 M25.2 M8.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.237.017.6487
Slightly volatile
Stock Based Compensation To Revenue0.03550.03990.0436
Slightly volatile
Capex To Depreciation1.01.790.7922
Slightly volatile
EV To Sales9.0710.2111.1393
Slightly volatile
Payables Turnover0.160.14250.6207
Slightly volatile
Sales General And Administrative To Revenue0.10.110.1239
Slightly volatile
Research And Ddevelopement To Revenue0.440.50.5424
Slightly volatile
Capex To Revenue0.00660.00750.0081
Slightly volatile
Cash Per Share10.09.524.1107
Slightly volatile
Days Payables Outstanding1.2 K2.3 K873
Slightly volatile
Income Quality0.920.890.8904
Slightly volatile
Current Ratio13.8818.6218.2824
Pretty Stable
Capex Per Share0.02510.02390.0104
Slightly volatile
Revenue Per Share1.581.781.9429
Slightly volatile
Interest Debt Per Share0.280.290.6644
Slightly volatile
Debt To Assets0.02510.02650.1479
Pretty Stable
Days Of Payables Outstanding1.2 K2.3 K873
Slightly volatile
Pretax Profit Margin0.370.420.4554
Slightly volatile
Effective Tax Rate0.01550.01750.0191
Slightly volatile
Long Term Debt To Capitalization1.461.390.4799
Slightly volatile
Total Debt To Capitalization0.02620.02760.1554
Pretty Stable
Quick Ratio13.8818.6218.2824
Pretty Stable
Net Income Per E B T0.780.880.9629
Slightly volatile
Cash Ratio1.411.981.4283
Slightly volatile
Operating Cash Flow Sales Ratio0.310.350.3803
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.910.9875
Slightly volatile
Fixed Asset Turnover28.6332.2135.1591
Slightly volatile
Debt Ratio0.02510.02650.1479
Pretty Stable
Price Sales Ratio6.237.017.6487
Slightly volatile
Asset Turnover0.30.350.3766
Slightly volatile
Net Profit Margin0.360.410.4462
Slightly volatile

Contineum Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap370 M326 M378.2 M
Slightly volatile
Enterprise Value459.1 M308 M527.8 M
Slightly volatile

Contineum Fundamental Market Drivers

About Contineum Therapeutics Financial Statements

Contineum Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Contineum Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue232.2 K208.5 K
Stock Based Compensation To Revenue 0.04  0.04 
Sales General And Administrative To Revenue 0.11  0.10 
Research And Ddevelopement To Revenue 0.50  0.44 
Capex To Revenue 0.01  0.01 
Revenue Per Share 1.78  1.58 
Ebit Per Revenue(0.29)(0.30)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Contineum Therapeutics is a strong investment it is important to analyze Contineum Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Contineum Therapeutics' future performance. For an informed investment choice regarding Contineum Stock, refer to the following important reports:
How To Invest In Contineum
Details
Is Contineum Stock a good investment?
Details
What is Contineum Therapeutics' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Contineum Therapeutics Correlation against competitors.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Will Pharmaceuticals sector continue expanding? Could Contineum diversify its offerings? Factors like these will boost the valuation of Contineum Therapeutics. Projected growth potential of Contineum fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Contineum Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(2.25)
Return On Assets
(0.21)
Return On Equity
(0.30)
Understanding Contineum Therapeutics requires distinguishing between market price and book value, where the latter reflects Contineum's accounting equity. The concept of intrinsic value - what Contineum Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Contineum Therapeutics' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Contineum Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Contineum Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Contineum Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY